시장보고서
상품코드
1738269

세계의 착상 전 유전자 검사 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 절차별, 제품별, 기술별, 용도별, 최종 사용자별, 지역별, 경쟁별(2020-2030년)

Preimplantation Genetic Testing Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Procedure, By Product, By Technology, By Application, By End User, By Region & Competition, 2020-2030F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 182 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 착상 전 유전자 검사 시장은 2024년에는 6억 5,530만 달러로 평가되었고, 2030년까지는 10억 5,387만 달러에 이를 것으로 예측되며, 예측 기간 중 CAGR은 8.20%를 나타낼 전망입니다.

착상 전 유전자 검사(PGT)는 보조 생식 기술의 중추적인 절차로, 주로 체외 수정(IVF) 과정에서 착상 전 배아의 유전적 이상을 선별하기 위해 사용됩니다. PGT의 두 가지 주요 유형에는 염색체 이수성을 식별하는 PGT-A와 단일성 장애를 감지하는 PGT-M이 있습니다. 이 검사는 임신 성공 확률을 높이고 유전 질환의 전염 위험을 줄여줍니다. 배아 선택을 개선하고 유전적 위험을 완화할 수 있는 PGT는 특히 유전적 소인이 있는 부부 사이에서 전 세계적으로 주목받고 있습니다. 인식의 증가, 유전자 진단의 발전, 불임 서비스에 대한 접근성 증가가 이 시장의 확장을 촉진하고 있습니다.

시장 개요
예측 기간 2026-2030년
시장 규모(2024년) 6억 5,530만 달러
시장 규모(2030년) 10억 5,387만 달러
CAGR(2025-2030년) 8.20%
급성장 부문 착상 전 유전자 진단(PGD)
최대 시장 유럽

주요 시장 성장 촉진요인

유전 질환의 발생률 증가

주요 시장 과제

윤리적, 도덕적 우려

주요 시장 동향

착상 전 유전자 검사(PGT) 서비스를 제공하는 불임 클리닉의 수 증가

목차

제1장 제품 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 착상 전 유전자 검사 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율 및 예측
    • 절차별(착상 전 유전자 검사, 착상 전 유전자 진단)
    • 제품별(시약 및 소모품, 기기, 소프트웨어)
    • 기술별(차세대 시퀀싱(NGS), 중합효소 연쇄반응(PCR), 형광 현장 혼성화(FISH), 기타)
    • 용도별(염색체 이상, X연쇄 질환, 배아 검사, 이수성 검사, HLA 타이핑, 기타)
    • 최종 사용자별(불임 클리닉, 병원, 진단센터, 연구센터, 학술연구실)
    • 지역별
    • 기업별(2024년)
  • 시장 맵

제6장 북미의 착상 전 유전자 검사 시장 전망

  • 시장 규모와 예측
  • 시장 점유율 및 예측
  • 북미 : 국가별 분석
    • 미국
    • 캐나다
    • 멕시코

제7장 유럽의 착상 전 유전자 검사 시장 전망

  • 시장 규모와 예측
  • 시장 점유율 및 예측
  • 유럽 : 국가별 분석
    • 독일
    • 영국
    • 이탈리아
    • 프랑스
    • 스페인

제8장 아시아태평양의 착상전 유전자검사 시장 전망

  • 시장 규모와 예측
  • 시장 점유율 및 예측
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주

제9장 남미의 착상 전 유전자 검사 시장 전망

  • 시장 규모와 예측
  • 시장 점유율 및 예측
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제10장 중동 및 아프리카의 착상 전 유전자 검사 시장 전망

  • 시장 규모와 예측
  • 시장 점유율 및 예측
  • 중동 및 아프리카 : 국가별 분석
    • 남아프리카
    • 사우디아라비아
    • 아랍에미리트(UAE)

제11장 시장 역학

  • 성장 촉진요인
  • 과제

제12장 시장 동향과 발전

  • 최근 동향
  • 제품 출시
  • 합병과 인수

제13장 세계의 착상 전 유전자 검사 시장 : SWOT 분석

제14장 경쟁 구도

  • California Pacific Medical Center(CPMC)
  • CombiMatrix Corp
  • CooperSurgical, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genea Limited
  • Genesis Genetics
  • Good Start Genetics, Inc.
  • IGENOMIX
  • Illumina, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings

제15장 전략적 제안

제16장 기업 소개와 면책사항

HBR 25.06.11

The Global Preimplantation Genetic Testing Market was valued at USD 655.30 Million in 2024 and is projected to reach USD 1053.87 Million by 2030, growing at a CAGR of 8.20% during the forecast period. Preimplantation Genetic Testing (PGT) is a pivotal procedure within assisted reproductive technologies, primarily used during in vitro fertilization (IVF) to screen embryos for genetic abnormalities prior to implantation. The two key types of PGT include PGT-A, which identifies chromosomal aneuploidies, and PGT-M, which detects monogenic disorders. This testing enhances the chances of a successful pregnancy and reduces the risk of transmitting hereditary diseases. With its capacity to improve embryo selection and mitigate genetic risks, PGT is gaining traction globally, especially among couples with known genetic predispositions. Growing awareness, advancements in genetic diagnostics, and increased access to fertility services are fueling the expansion of this market.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 655.30 Million
Market Size 2030USD 1053.87 Million
CAGR 2025-20308.20%
Fastest Growing SegmentPre-implantation genetic diagnosis (PGD)
Largest MarketEurope

Key Market Drivers

Rising Incidence of Genetic Disorders

A major factor propelling the preimplantation genetic testing market is the increasing prevalence of genetic disorders across global populations. These conditions affect a significant percentage of live births and early-life diagnoses, with approximately 5.3% of individuals worldwide being diagnosed with a genetic condition by age 25. This rising incidence has heightened the demand for early detection and intervention solutions, particularly among couples with hereditary risk factors. In regions such as the Middle East and North Africa, where consanguineous marriages are prevalent, the uptake of PGT is particularly strong due to elevated genetic risks. PGT offers a proactive approach to identifying embryos unaffected by hereditary diseases, improving reproductive outcomes and reducing long-term healthcare burdens. Its adoption is further supported by growing public and clinical awareness about genetic disorders and their impact on offspring health.

Key Market Challenges

Ethical And Moral Concern

Ethical and moral concerns surrounding the use of PGT remain a prominent challenge in the market. The technology's potential to enable selection based on non-medical traits-such as physical appearance or cognitive abilities-raises fears of societal discrimination and the possible emergence of "designer babies." These concerns fuel debates about fairness, equity, and human diversity. Additionally, the screening and possible discarding of embryos with genetic conditions is a contentious issue, particularly in societies where abortion and embryo manipulation are morally or religiously opposed. Such dilemmas pose regulatory hurdles and may limit acceptance and accessibility in certain regions, thereby restraining the market's growth despite its clinical potential.

Key Market Trends

Growing Number of Fertility Clinics Offering Preimplantation Genetic Testing (PGT) Services

An expanding network of fertility clinics offering PGT services is a notable trend boosting market accessibility and growth. As these clinics extend their reach into diverse geographies, patients in both urban and remote areas gain improved access to advanced reproductive and genetic services. The integration of PGT into fertility clinic offerings enhances the convenience of comprehensive care by combining IVF and genetic diagnostics under one roof. This growing availability fosters competitive service provision, technological innovation, and cost efficiencies. Furthermore, broader adoption of PGT in clinical settings is accelerating advancements in testing accuracy, turnaround times, and scope, including the ability to detect an expanded range of genetic abnormalities-thereby improving patient outcomes and expanding the market's potential.

Key Market Players

  • California Pacific Medical Center (CPMC)
  • CombiMatrix Corp
  • CooperSurgical, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genea Limited
  • Genesis Genetics
  • Good Start Genetics, Inc.
  • IGENOMIX
  • Illumina, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings

Report Scope:

In this report, the Global Preimplantation Genetic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Preimplantation Genetic Testing Market, By Procedure:

  • Preimplantation Genetic Screening
  • Preimplantation Genetic Diagnosis

Preimplantation Genetic Testing Market, By Product:

  • Reagents and Consumables
  • Instruments
  • Software

Preimplantation Genetic Testing Market, By Technology:

  • Next Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Fluorescent In-Situ Hybridization (FISH)
  • Others

Preimplantation Genetic Testing Market, By Application:

  • Chromosomal Abnormalities
  • X-linked Diseases
  • Embryo Testing
  • Aneuploidy Screening
  • HLA Typing
  • Other

Preimplantation Genetic Testing Market, By End User:

  • Fertility Centers
  • Hospitals
  • Diagnostic Centers
  • Research Centers and Academic Labs

Preimplantation Genetic Testing Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Preimplantation Genetic Testing Market.

Available Customizations:

Global Preimplantation Genetic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Preimplantation Genetic Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Procedure (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis)
    • 5.2.2. By Product (Reagents and Consumables, Instruments, Software)
    • 5.2.3. By Technology (Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescent In-Situ Hybridization (FISH), Others)
    • 5.2.4. By Application (Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, Aneuploidy Screening, HLA Typing, Other)
    • 5.2.5. By End User (Fertility Centers, Hospitals, Diagnostic Centers, Research Centers and Academic Labs)
    • 5.2.6. By Region
    • 5.2.7. By Company (2024)
  • 5.3. Market Map

6. North America Preimplantation Genetic Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Procedure
    • 6.2.2. By Product
    • 6.2.3. By Technology
    • 6.2.4. By Application
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Preimplantation Genetic Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Procedure
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Technology
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Preimplantation Genetic Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Procedure
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Technology
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Preimplantation Genetic Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Procedure
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Technology
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By End User

7. Europe Preimplantation Genetic Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Procedure
    • 7.2.2. By Product
    • 7.2.3. By Technology
    • 7.2.4. By Application
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Preimplantation Genetic Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Procedure
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Technology
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. United Kingdom Preimplantation Genetic Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Procedure
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Technology
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. Italy Preimplantation Genetic Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Procedure
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Technology
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User
    • 7.3.4. France Preimplantation Genetic Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Procedure
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By Technology
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Preimplantation Genetic Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Procedure
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By Technology
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By End User

8. Asia-Pacific Preimplantation Genetic Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Procedure
    • 8.2.2. By Product
    • 8.2.3. By Technology
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Preimplantation Genetic Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Procedure
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Technology
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. India Preimplantation Genetic Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Procedure
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Technology
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Preimplantation Genetic Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Procedure
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Technology
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Preimplantation Genetic Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Procedure
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By Technology
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Preimplantation Genetic Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Procedure
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By Technology
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. South America Preimplantation Genetic Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Procedure
    • 9.2.2. By Product
    • 9.2.3. By Technology
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Preimplantation Genetic Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Procedure
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Technology
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. Argentina Preimplantation Genetic Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Procedure
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Technology
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. Colombia Preimplantation Genetic Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Procedure
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Technology
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User

10. Middle East and Africa Preimplantation Genetic Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Procedure
    • 10.2.2. By Product
    • 10.2.3. By Technology
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Preimplantation Genetic Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Procedure
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Technology
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Saudi Arabia Preimplantation Genetic Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Procedure
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Technology
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. UAE Preimplantation Genetic Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Procedure
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Technology
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Preimplantation Genetic Testing Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. California Pacific Medical Center (CPMC)
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. CombiMatrix Corp
  • 14.3. CooperSurgical, Inc.
  • 14.4. F. Hoffmann-La Roche Ltd.
  • 14.5. Genea Limited
  • 14.6. Genesis Genetics
  • 14.7. Good Start Genetics, Inc.
  • 14.8. IGENOMIX
  • 14.9. Illumina, Inc.
  • 14.10.Invitae Corporation
  • 14.11.Laboratory Corporation of America Holdings

15. Strategic Recommendations

16. About Us & Disclaimer

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제